The ultrastructural localization of amines, amino acids and peptides in the brain

Light and electron microscopic immunocytochemical analysis of the noradrenaline innervation of the rat visual cortex

Immunocytochemistry with an antiserum against noradrenaline was used to examine the organization and morphology of noradrenergic axons in the rat visual cortex. Observations with the light microscope confirmed earlier reports concerning the distribution pattern of noradrenergic fibres, and provided some further clues about their intracortical organization. Particularly striking was the finding of fibres which followed an oscillating course within the boundaries of layers II-IV as they ran in the mediolateral direction. Examination of the morphological characteristics of noradrenaline-containing axon terminals in serial ultrathin sections has provided further evidence that the vast majority (87.6%) form conventional synapses in the visual and frontoparietal cortex, and has given clues about the postsynaptic elements involved in these synaptic contacts; they are, in decreasing frequency, spines, dendritic shafts of various diameters, and pyramidal and non-pyramidal somata. In addition, a few labelled terminals were visualized in close association with intracerebral capillaries.

Vasopressin and brain development: studies using the Brattleboro rat

Anomalies in hormonal and neurotransmitter status during early stages of brain development, can lead to lifespan alterations in the functioning of central systems. The neuropeptide vasopressin is nowadays recognized as a putative neurotransmitter, after years of study on its neurosecretory hormonal aspect in water metabolism. Since vasopressin is moreover present early in the brain, and has various mitogenic, metabolic and physiological actions, one might expect vasopressin to be of importance for normal brain development as well. Indeed, the absence of brain vasopressin in the Brattleboro mutant rat coincides with impaired brain development, and some physiological and behavioral defects of these rats are not adjusted by treatment with vasopressin. Regionally the cerebellum seems to be the most affected brain area, both morphologically and biochemically. Only when vasopressin supplementation was done prenatally, this disturbed growth could be restored, which suggests an early role for vasopressin in neurogenesis. Enhanced levels of vasopressin during the perinatal period on the other hand, have been shown to affect permanently the 'setting' of peripheral vasopressin functions in cardiovascular and renal regulatory systems. It is not excluded as yet that after such treatments central organization of vasopressin systems is not impaired as well.

Neuropeptide effects on brain development to be expected from behavioral teratology

A wealth of literature has become available about lasting functional consequences of perinatal psychotropic drug exposure, having affected brain development in a subtle rather than gross structural way (behavioral teratology or functional neuroteratology). The underlying mechanism is thought to result from changing levels of neurotransmitters during neurogenesis induced by these neuroactive drugs, which as a consequence appears to lead to impaired cell acquisition and receptor setting i.e., to irreversible changes in particular neuronal circuitries. Neuropeptides are true candidates for a neurotransmission function as well, and are also present early in brain development. As for the classical neurotransmitters, a role for neuropeptides in the growth and functional organization of the nervous system, might therefore be expected. Anomalies in neuropeptide levels also would lead to functional neuroteratology. Although not overwhelming, several studies support this view, and the current state is summarized in this paper: a trophic role for some neuropeptides as well as neuroteratological effects upon perinatal manipulation for others were revealed. However, more detailed studies are necessary, certainly also because of the crying need for exposing possible adverse effects at a time when clinical applications of neuropeptides and their analogues are becoming a mode.